{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:14:43Z","timestamp":1783332883376,"version":"3.54.6"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Aurinia Pharmaceuticals Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the long-term safety and efficacy of voclosporin in Asian patients with lupus nephritis who completed the AURORA 1 phase III study and enrolled in the AURORA 2 phase III continuation study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc analysis included 3\u00a0years of pooled data (AURORA 1 and AURORA 2). The double-blinded voclosporin or control treatment assigned in AURORA 1 was continued in AURORA 2. Safety and efficacy (renal response) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty Asian patients were included (voclosporin, n\u2009=\u200930; control, n\u2009=\u200930). Adverse events occurred in 93.3 and 100.0% of voclosporin-treated and control patients, respectively. More patients in the voclosporin vs control group experienced decreased glomerular filtration rate (26.7 vs. 6.7%) and hypertension (33.3 vs. 10.0%); rates of study drug discontinuation due to adverse events were also lower (3.3 vs. 26.7%). Respective rates of urine protein creatinine ratio\u2009\u22640.5\u00a0mg\/mg achievement were 90.0 and 56.7%; median time to achievement was significantly shorter with voclosporin (6.3 vs. 26.7\u00a0months; P\u2009=\u00a0.001). Safety and efficacy were similar to the AURORA 2 overall population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Asian patients with active lupus nephritis had sustained proteinuria reductions and a shorter time to proteinuria reduction with voclosporin versus control; voclosporin was well-tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf121","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:01:13Z","timestamp":1765976473000},"page":"581-587","source":"Crossref","is-referenced-by-count":0,"title":["Long-term safety and efficacy of voclosporin in Asian patients with lupus nephritis: A post hoc analysis of the AURORA 2 trial"],"prefix":"10.1093","volume":"36","author":[{"given":"Tatsuya","family":"Atsumi","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Navarra","sequence":"additional","affiliation":[{"name":"University of Santo Tomas Hospital , Manila,","place":["Philippines"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Truman","sequence":"additional","affiliation":[{"name":"Truman Statistical Services , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Nakata","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Medical Affairs, Otsuka Pharmaceutical Co., Ltd , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2026070605220783000_ref1","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/jcm10040670","article-title":"Management of lupus nephritis","volume":"10","author":"Tamirou","year":"2021","journal-title":"J Clin Med"},{"key":"2026070605220783000_ref2","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1177\/0961203320932219","article-title":"Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression","volume":"29","author":"Mahajan","year":"2020","journal-title":"Lupus"},{"key":"2026070605220783000_ref3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/mr\/roac143","article-title":"Autoantibodies in lupus nephritis useful in distinguishing proliferative nephritis from membranous nephritis","volume":"33","author":"Asanuma","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026070605220783000_ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000511268","article-title":"Update on lupus nephritis: looking for a new vision","volume":"145","author":"Morales","year":"2021","journal-title":"Nephron"},{"key":"2026070605220783000_ref5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026070605220783000_ref6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/acr.20683","article-title":"Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality","volume":"64","author":"Jakes","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026070605220783000_ref7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/1529-0131(200112)45:6&lt;494::aid-art374&gt;3.0.co;2-m","article-title":"A comparative study of the clinical manifestations of systemic lupus erythematosus in Caucasians in Rochester, Minnesota, and Chinese in Singapore, from 1980 to 1992","volume":"45","author":"Thumboo","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2026070605220783000_ref8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/25785826.2023.2264023","article-title":"A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7\/8 antagonist through academia-industry-government collaboration","volume":"47","author":"Tanaka","year":"2024","journal-title":"Immunol Med"},{"key":"2026070605220783000_ref9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026070605220783000_ref10","author":"Aurinia Pharmaceuticals Inc"},{"key":"2026070605220783000_ref11","author":"European Medicines Agency"},{"key":"2026070605220783000_ref12","doi-asserted-by":"publisher","first-page":"e31465","DOI":"10.1371\/journal.pone.0031465","article-title":"Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of na\u00efve T cells into cytokine-producing mature T cells","volume":"7","author":"Tsuda","year":"2012","journal-title":"PLoS One"},{"key":"2026070605220783000_ref13","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.3390\/jcm11175017","article-title":"Predictors of early response, flares, and long-term adverse renal outcomes in proliferative lupus nephritis: a 100-month median follow-up of an inception cohort","volume":"11","author":"Kapsia","year":"2022","journal-title":"J Clin Med"},{"key":"2026070605220783000_ref14","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"2026070605220783000_ref15","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/j.1600-6143.2011.03763.x","article-title":"PROMISE investigators. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation","volume":"11","author":"Busque","year":"2011","journal-title":"Am J Transplant"},{"key":"2026070605220783000_ref16","doi-asserted-by":"publisher","first-page":"bqaa162","DOI":"10.1210\/endocr\/bqaa162","article-title":"Differential effects of voclosporin and tacrolimus on insulin secretion from human islets","volume":"161","author":"Kolic","year":"2020","journal-title":"Endocrinology"},{"key":"2026070605220783000_ref17","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/ndt\/gfab022","article-title":"Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE","volume":"37","author":"Gelder","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026070605220783000_ref18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026070605220783000_ref19","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"Oorschot","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2026070605220783000_ref20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/mr\/roab069","article-title":"A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026070605220783000_ref21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026070605220783000_ref22","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/mr\/road092","article-title":"The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis","volume":"34","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026070605220783000_ref23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/mr\/roae030","article-title":"Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib","volume":"34","author":"Tanaka","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026070605220783000_ref24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1067\/mcp.2001.113183","article-title":"The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups","volume":"69","author":"Mancinelli","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"2026070605220783000_ref25","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1111\/ajt.15385","article-title":"Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: a comparison of four ancestry groups","volume":"19","author":"Mohamed","year":"2019","journal-title":"Am J Transplant"},{"key":"2026070605220783000_ref26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026070605220783000_ref27","first-page":"687","article-title":"Clinical analysis of multi-target treatment for complex lupus nephritis","volume":"14","author":"Ye","year":"2022","journal-title":"Am J Transl Res"},{"key":"2026070605220783000_ref28","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/1744666X.2021.1967747","article-title":"Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis","volume":"17","author":"Mej\u00eda-Vilet","year":"2021","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf121\/65998954\/roaf121.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/581\/65998954\/roaf121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/581\/65998954\/roaf121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:22:46Z","timestamp":1783329766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/4\/581\/8383386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,18]]},"published-print":{"date-parts":[[2026,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf121","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2025,12,18]]}}}